닥플 플러스
2026 International Congress of Diabetes and Metabolism(3일차)
대한당뇨병학회
연수평점 :6점
오프라인
주관
대한당뇨병학회
교육일자
2026-10-17
수강료
450,000원
교육형태
오프라인
등록일시
2026-08-06
교육시간
25시간 20분
연수평점
6점
장소
서울특별시 서울, 마곡코엑스(1층, 3층, 4층)
교육종류
내과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-10-17 | 08:00~08:15 | Phenomapping-driven antiplatelet therapy for primary prevention in diabetic patients: who gets what? | 윤재승(가톨릭의대 내과) | - |
| 2026-10-17 | 08:00~08:15 | The necessity of SGLT2i in the management of CKM syndrome | 류영상(조선의대 내과) | - |
| 2026-10-17 | 08:00~08:15 | Beyond statins: a new era of oral lipid-lowering therapy for statin-intolerant patients | 홍준화(을지의대 내과) | - |
| 2026-10-17 | 08:15~08:30 | The clinical importance of sulfonylurea and SGLT2 inhibitor in the management of type 2 diabetes | 양여리(가톨릭의대 내과) | - |
| 2026-10-17 | 08:15~08:30 | TZD+SGLT-2i combination therapy: benefits for diabetic complications and MASLD | 노은(서울의대 내과) | - |
| 2026-10-17 | 08:15~08:30 | Fenofibrate in cardiometabolic health: clinical utility and safety in dyslipidemia management | Richard O(University of Melbourne) | - |
| 2026-10-17 | 08:30~09:00 | 휴식 | - | - |
| 2026-10-17 | 09:00~09:25 | From cardiometabolic evidence to individualized CKM care | Per-Henrik Groop(University of Helsinki Finland) | - |
| 2026-10-17 | 09:25~09:50 | Recognizing high-risk CKM phenotypes beyond HbA1c | Yu Mi Kang(Harvard University USA) | - |
| 2026-10-17 | 09:50~10:15 | Synergistic use of cardiometabolic therapies across CKM stages | Hiddo Lambers Heerspink(University Medical Center Groningen) | - |
| 2026-10-17 | 09:00~09:25 | Oral non‑peptide GLP-1 receptor agonists: mechanisms and therapeutic potential in metabolic disease | Luc Van Gaal(Antwerp University) | - |
| 2026-10-17 | 09:25~09:50 | Achieve program: translating phase 3 evidence into clinical practice in type 2 diabetes | 조영민(서울의대 내과) | - |
| 2026-10-17 | 09:50~10:15 | Attain and beyond: clinical implications of phase 3 obesity trials in cardiometabolic care | 이승환(가톨릭의대 내과) | - |
| 2026-10-17 | 09:00~09:20 | Tissue engineering, biocompatible hydrogel, multifunctional nanoparticles, surface modified substrate | 황석연(서울대학교 화학생물공학부) | - |
| 2026-10-17 | 09:20~09:40 | Immune-evasive human islet-like organoids ameliorate diabetes | Eiji Yoshihara(UCLA USA) | - |
| 2026-10-17 | 09:40~10:00 | Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient | Shusen Wang(Nankai University China) | - |
| 2026-10-17 | 10:00~10:20 | Panel discussion | 이은영 이기현 김형석(가톨릭의대 내과 이화여대 약학대학 충남의대 생화학교실) | - |
| 2026-10-17 | 09:00~09:20 | Characteristics of beta-cell dysfunction in Korean T2D | 김남훈(고려의대 내과) | - |
| 2026-10-17 | 09:20~09:40 | Glucocentric view of beta-cell preservation | 원규장(영남의대 내과) | - |
| 2026-10-17 | 09:40~10:00 | Toward β-cell recovery in diabetes: quantitative imaging and stress-adaptive β-cell remodeling | Takaaki Murakami(Kyoto University Japan) | - |
| 2026-10-17 | 10:00~10:20 | Panel discussion | 이준엽 전재한 문준호(가톨릭의대 내과 경북의대 내과 서울의대 내과) | - |
| 2026-10-17 | 09:00~09:25 | Evolving treatment strategies in diabetic kidney disease: from RAAS blockade to MRA and GLP-1 RAs | 김미경(계명의대 내과) | - |
| 2026-10-17 | 09:25~09:50 | Current and emerging treatments for MASLD: an update | 한유진(계명의대 내과) | - |
| 2026-10-17 | 09:50~10:15 | Achieving and maintaining weight loss in patients with diabetes | 김보연(순천향의대 내과) | - |
| 2026-10-17 | 10:15~10:30 | 휴식 | - | - |
| 2026-10-17 | 10:30~11:10 | Evidence-based and updated CKM preventive strategies, clinical trials | Darren McGuire(University of Texas Southwestern Medical Center USA) | - |
| 2026-10-17 | 11:10~11:50 | MASLD: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment | Norbert Stefan(University Tübingen Germany) | - |
| 2026-10-17 | 11:50~12:05 | Transforming the trajectory of T2D treatment thorugh Early intensive invervention with GIP/GLP-1 Dual agonist | Luc Van Gaal(Antwerp University) | - |
| 2026-10-17 | 11:50~12:05 | IcoSema: redefining injectable therapy for type 2 diabetes | Ryo Suzuki(Tokyo Medical University) | - |
| 2026-10-17 | 11:50~12:05 | A new era of CKD and T2D management: a holistic approach with nsMRA | 서다혜(인하의대 내과) | - |
| 2026-10-17 | 11:50~12:05 | Advances in diabetes management clinical benefits of SGLT-2 inhibitors in combination therapy | 최종한(건국의대 내과) | - |
| 2026-10-17 | 12:05~12:20 | Rethinking diabetes care: why kidney protection can no longer wait | Per-Henrik Groop(University of Helsinki) | - |
| 2026-10-17 | 12:05~12:20 | The Importance of preventing shingles in diabetic patients and the role of endocrinologist | 박정환(한양의대 내과) | - |
| 2026-10-17 | 12:05~12:20 | The optimal combination therapy with TZD and SGLT2i | 정창희(울산의대 내과) | - |
| 2026-10-17 | 12:05~12:20 | Exploring clinical data for hypertensive patients with kidney disease | 정경혜(충남의대 내과) | - |
| 2026-10-17 | 12:20~13:20 | 점심식사 | - | - |
| 2026-10-17 | 13:20~13:40 | Lactation-driven metabolic reprogramming of adipose tissue | 문준호(서울의대 내과) | - |
| 2026-10-17 | 13:40~14:00 | CGM-derived glycemic trajectories reflect β-cell decline across dysglycemia | 이준엽(가톨릭의대 내과) | - |
| 2026-10-17 | 14:00~14:20 | Hidden in plain sight: redefining risk through lipids, adiposity, and pregnancy in metabolic disease | 정한나(한림의대 내과) | - |
| 2026-10-17 | 14:20~14:40 | Sympathetic circuit heterogeneity in multi-organ metabolic regulation | 주상현(KAIST) | - |
| 2026-10-17 | 13:20~13:45 | Modern treatment of CKD in diabetes | Per-Henrik Groop(University of Helsinki) | - |
| 2026-10-17 | 13:45~14:10 | Anchoring early CKM care: EMPA FIT vs metformin in treatment-naïve T2D | 임수(서울의대 내과) | - |
| 2026-10-17 | 14:10~14:35 | Expanding CKM to liver health with GLP-1/GCGR dual agonist (phase 3 updates) | 홍준화(을지의대 내과) | - |
| 2026-10-17 | 13:20~13:45 | Aging, kidney health, and diabetes: epidemiologic implications for healthy longevity | Shigeo Horie(Juntendo University Japan) | - |
| 2026-10-17 | 13:45~14:10 | Towards validating the unitary hypothesis: are fundamental aging mechanisms in adipose depots concentrated within tissue crown-like structures? | James L. Kirkland(Cedars-Sinai Medical Center USA) | - |
| 2026-10-17 | 14:10~14:35 | Senotherapeutics: translating research into clinical reality | 전옥희(고려의대) | - |
| 2026-10-17 | 13:20~13:40 | Taming the 'invisible' rice spike: why reliable PPG control matters in resource-limited settings | Olive De Guzman-Quizon(Manila Doctors Hospital) | - |
| 2026-10-17 | 13:40~14:00 | Fighting obesity in Asia: beyond weight loss, gaining health | Chan Siew Pheng(Subang Jaya Medical Centre) | - |
| 2026-10-17 | 14:00~14:20 | Protecting the vulnerable: safety strategies for older adults & CKD patients | Navaporn Napartivaumnuay(Rajvithi Hospital) | - |
| 2026-10-17 | 14:20~14:40 | Time is pancreas: why Korea prioritizes early combination therapy | 김소헌(인하의대 내과) | - |
| 2026-10-17 | 13:20~13:45 | Differentiating type 1 and type 2 diabetes: diagnostic challenges and treatment strategies | 진상만(성균관의대 내과) | - |
| 2026-10-17 | 13:45~14:10 | Key educational points for insulin pump therapy | 이수지(강북삼성병원) | - |
| 2026-10-17 | 14:10~14:35 | Optimizing resistance exercise in patients with diabetes on injectable therapies | 정승재(삼성서울병원) | - |
| 2026-10-17 | 13:20~13:45 | The one ring of diabetology, everything about insulin | 문준성(영남의대 내과) | - |
| 2026-10-17 | 13:45~14:10 | How CGM has transformed diabetes care | 김재현(성균관의대 내과) | - |
| 2026-10-17 | 14:10~14:35 | Landmark studies that changed the paradigm of diabetes treatment | 김신곤(고려의대 내과) | - |
| 2026-10-17 | 14:35~14:50 | 휴식 | - | - |
| 2026-10-17 | 14:50~15:15 | Expanding the evidence of diabetes technology in special populations: older adults to pregnancy | 유지희(중앙의대 내과) | - |
| 2026-10-17 | 15:15~15:40 | Beyond prevention: CGM as a tool for treatment optimization in pre-type 2 diabetes | Rimei Nishimura(Jikei University Japan) | - |
| 2026-10-17 | 15:40~16:05 | Current status and future perspectives of fully closed-loop systems for type 2 diabetes in Korea | 문선준(성균관의대 내과) | - |
| 2026-10-17 | 14:50~15:15 | Managing hyperkalemia in diabetes | Hideki Yokoi(Kumamoto University Japan) | - |
| 2026-10-17 | 15:15~15:40 | Managing uncontrolled hypertension in diabetes | 이해영(서울대학교병원) | - |
| 2026-10-17 | 15:40~16:05 | Managing obesity in diabetes | 유성훈(한양의대 내과) | - |
| 2026-10-17 | 14:50~15:15 | Reappraising pioglitazone: metabolic modification and organ protection | Kenneth Cusi(University of Florida) | - |
| 2026-10-17 | 15:15~15:40 | Re-evaluating macrovascular outcomes and practical management method of pioglitazone | 홍준화(을지의대 내과) | - |
| 2026-10-17 | 15:40~16:05 | Complementary combination strategies: positioning pioglitazone in the era of modern agents | 김규리(성균관의대 내과) | - |
| 2026-10-17 | 14:50~15:10 | Characteristics of diabetes in East Asia with a focus on nonobese phenotype | Yuji Yamazaki(Kansai Electric Power Medical Research Institute) | - |
| 2026-10-17 | 15:10~15:30 | Lean diabetes in South Asians: what exactly is it? | Viswanathan Mohan(Madras Diabetes Research Foundation) | - |
| 2026-10-17 | 15:30~15:45 | Secondary causes of diabetes | Lee-Ling Lim(Universiti Malaya) | - |
| 2026-10-17 | 15:45~16:00 | Lean diabetes: 20-year trends in its prevalence and clinical features among Korean adults | 이주희(충남의대 내과) | - |
| 2026-10-17 | 16:00~16:10 | Panel discussion | 김혜진 허지혜(아주의대 내과 한림의대 내과) | - |
| 2026-10-17 | 14:50~15:10 | Nicotinamide riboside attenuates ritonavir-induced lipodystrophy and systemic side effects | Yan Zhang(Central Hospital of Dalian University of Technology China) | - |
| 2026-10-17 | 15:10~15:30 | Targeting carbonic anhydrase 3 enhances skeletal muscle regeneration via a non-canonical AKT-GSK3β-PGC1α pathway to rejuvenate aged satellite cells | Darren R. Williams(GIST) | - |
| 2026-10-17 | 15:30~15:50 | Mitochondrial metabolic reprogramming to combat sarcopenia | 강종순(성균관대학교 의과대학) | - |
| 2026-10-17 | 15:50~16:10 | Panel discussion | 서재명 오창명 전재한(카이스트 GIST 경북의대 내과) | - |
비고
Early bird 등록(2026년 8월 10일까지): 전문의(KDA 회원 240,000원 / 비회원 300,000원), 전공의·간호사·영양사·사회복지사·약사·연구원·운동처방사·관련 분야 교수 및 기타(KDA 회원 140,000원 / 비회원 200,000원)Advance 등록(2026년 9월 11일까지): 전문의(KDA 회원 280,000원 / 비회원 350,000원), 전공의 등(KDA 회원 180,000원 / 비회원 230,000원)현장등록(2026년 10월 15일~17일): 전문의(KDA 회원 370,000원 / 비회원 450,000원), 전공의 등(KDA 회원 250,000원 / 비회원 270,000원)
문의처
담당자
이연주
연락처
02-714-9071
이메일
diabetes@kams.or.kr